ganglioneuroma/seizures

We describe the clinical, radiologic, and EEG features of 3 children who had dysplastic gangliocytomas of the cerebral hemispheres and drug resistant partial seizures that began in infancy. Following cortical resection, 2 are seizure-free and the third almost seizure-free. The dysplastic

Ganglioneuromas (GN) are neural crest cell-derived tumors which may coexist with pheochromocytomas, secrete various neuropeptides or the symptoms may mimic that of a pheochromocytoma, producing hypertension or a hypotensive crisis during anesthesia for these tumors. We report here the case of a

A dysplastic neuronal lesion of the floor of the fourth ventricle (DNFFV) causes hemifacial seizures (HFS) from early infancy. However, it is still controversial whether HFS is generated by the facial nerve nucleus or cerebellar cortex. In this study, we confirm a direct correlation between the

Cerebellar lesions have classically been considered not to cause epilepsy. However, previous reports have attributed seizures, beginning as hemifacial spasms to lesions of the cerebellar peduncles. We report an example of paroxysmal facial contractions associated with a cerebellar gangliocytoma. The

Neoplasms and (non-neoplastic) focal dysplasias may coexist as a cause of seizures in both the developing and mature brain. Low grade neoplastic lesions (ganglioglioma/gangliocytoma) may present with seizures, and distinction of these lesions from focal cortial dysplasia is difficult on standard

We report a case of gangliocytoma at a cortical and subcortical area in the right parietal lobe. The patient had a generalized seizure at 11 years of age. The MRI shows an ill-demarcated high intensity area in T2 weighted images including an enhancing tumor of 10 mm in diameter. At first, the tumor

Cerebellar gangliocytoma can correspond to Lhermitte-Duclos disease, a benign hamartomatous malformation encountered in young adults. It can also be a part of gangliogliomas/gangliocytomas family, which usually encompasses temporal pediatric neoplasms associated with longstanding seizures. We report

Epilepsy surgery has been demonstrated to be an effective alternative treatment for intractable partial or localization related epilepsy. Primary intracranial neoplasms and other structural lesions of the brain are important etiological factors in patients with partial seizure disorders. A

The diagnosis of brain tumour could not be made in 91 cases at the first investigation in a group of 1155 brain tumours. Slowly growing gliomas causing only epileptic fits and no other symptoms are especially difficult to diagnose. Of 21 personal observations of tumour seizures, in which the

OBJECTIVE Seizures frequently impact the quality of life of patients with low grade tumors. Management is often based on best clinical judgment. We examined factors that correlate with seizure outcome to optimize seizure management. METHODS Patients with supratentorial low-grade tumors evaluated at

Three children were examined who had surgery to remove gangliocytomas in order to control seizures that were refractory to medical therapy. The CT characteristics of gangliocytomas are those of a hyperdense lesion that does not demonstrate contrast enhancement. The MR findings show a region of mixed

Electrocortical stimulation mapping (ESM) is the clinical standard for localizing critical sensorimotor and language functions, but other functions can be assessed with this technique as well. The authors describe an 8-year-old girl with a left frontal desmoplastic gangliocytoma and medically

From January 1983 to April 1988, 40 cases of epilepsy were treated surgically. There were 15 cases of posttraumatic cicatrix, 5 cases of grade I astrocytoma, 9 cases of diffuse gliosis, 4 cases of vascular malformation, 1 case of calcification and cicatrix of temporal lobe, 2 cases of microglia

OBJECTIVE The object of this study was to delineate long-term results of the surgical treatment of pediatric tumors classified as ganglioglioma or gangliocytoma. METHODS A cohort of consecutive patients 19 years or younger who had undergone primary resection of CNS tumors during the years 1980-2016